XOMA Royalty Corporation (XOMAP) News

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has...

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty...

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 8-K - Current report

FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

EMERYVILLE, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty...

Form 4 - Statement of changes in beneficial ownership of securities

XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty...

Form 8-K - Current report

XOMA Announces Stock Repurchase Program of up to $50 Million

EMERYVILLE, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), the biotech royalty...

XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the...

Form 8-K - Current report

XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties

Low-cost financing capitalizes on XOMA’s $14 million acquisition of VABYSMO® (faricimab) royalties in 2021...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value

Received $6.6 million in cash receipts during the quarter related to our growing royalty base and certain...